KRAS and metastatic malignant neoplasm in the lymph nodes: KRAS exon 2 mutation appeared more frequent in older patients (average age: 67.7 years old vs 64.9 years old; P = 0.036) and was associated with higher lymph node metastasis rate (52.3% vs 41.6%; P = 0.046).